GlassScriptPhysician profile
Jaime Steinsapir
NPI 1396784344
$2,781.61
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,033 · 2020: $155 · 2021: $493 · 2022: $84.88 · 2024: $15.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tosoh Bioscience, INC. | $1,078.00 | 2019 | |
| Welch Allyn | $492.63 | 2021 | |
| Novo Nordisk INC | $204.01 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $198.13 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $119.12 | 2019 | |
| Mannkind Corporation | $107.02 | 2019 | |
| Amgen INC. | $61.54 | 2019 | |
| Lilly USA, LLC | $53.04 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.87 | 2019 | |
| Sanofi Pasteur INC. | $45.46 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $37.97 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $34.96 | 2019 | |
| Grt US Holding, INC. | $33.06 | 2022 | |
| Quidel Corporation | $32.32 | 2019 | |
| Amarin Pharma, INC. | $29.48 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $25.48 | 2019 | |
| Medtronic Minimed, INC. | $21.54 | 2019 | |
| Radius Health, INC. | $20.12 | 2019 | |
| Corcept Therapeutics | $19.34 | 2022 | |
| Bigfoot Biomedical INC | $16.41 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.07 | 2022 | |
| Boston Scientific Corporation | $15.51 | 2024 | Wavewriter Alpha Prime 16 |
| Abbvie INC. | $15.10 | 2019 | |
| Lifescan, INC. | $14.58 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.66 | 2020 | |
| Antares Pharma, INC. | $12.23 | 2019 | |
| Cardiovascular Systems INC. | $11.96 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Steinsapir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.